European Commission expands Trodelvy use in metastatic breast cancer
The European Commission expands the role of Gilead’s Trodelvy in first-line metastatic triple-negative breast cancer across PD-L1 status.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
EU expands Gilead Trodelvy role in metastatic breast cancer
The European Commission grants marketing authorization for Gilead’s Trodelvy with Keytruda in first-line PD-L1-positive metastatic triple-negative breast cancer and expands its role across PD-L1 status.